Table 3.
Base case results: observed and estimated pneumococcal disease cases with and without a universal infant pneumococcal conjugate vaccine program, 2005–2017
| Parameter | With infant PCV Immunization program |
Without infant PCV Immunization program |
Incremental |
|---|---|---|---|
| Outcomes | |||
| Cases of: | |||
| Bacteremia | 27,690 | 41,951 | − 14,261 |
| Meningitis | 4138 | 6269 | − 2131 |
| Non-hospitalized pneumonia | 403,721 | 666,693 | − 85,799 |
| Hospitalized pneumonia | 176,039 | 269,554 | − 16,260 |
| Non-hospitalized otitis media | 10,683,837 | 12,259,328 | − 1,575,491 |
| Hospitalized otitis media | 475,351 | 551,293 | − 75,942 |
| Deaths | 23,850 | 25,046 | − 1195 |
| Total life years | 358,103,104 | 358,084,569 | 18,535 |
| Total QALYs | 303,508,288 | 303,483,953 | 24,335 |
| Costs | |||
| Vaccine-related costs | $814,141,402 | $0 | $814,141,402 |
| IPD costs | $465,646,815 | $710,358,982 | − $244,712,167 |
| Pneumonia costs | $1,980,008,623 | $2,113,761,080 | − $133,752,457 |
| Otitis media costs | $2,277,040,418 | $2,631,257,706 | − $354,217,288 |
| Total costs | $5,536,837,258 | $5,455,377,768 | $81,459,490 |
| ICER | $3347 |
ICER incremental cost-effectiveness ratio, IPD invasive pneumococcal disease, PCV pneumococcal conjugate vaccine, QALY quality-adjusted life year